ClinicalTrials.gg
CompletedNCT05267613EEUpdated Oct 13, 2026

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

A Phase 3 interventional study of Nexium 20mg and Nexium 10mg in Erosive Esophagitis, sponsored by AstraZeneca. Completed at 41 sites in 10 countries. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
47th of 66
53 · median 125
Started
2022
the only one that year
Phase 3
15 of 67
none open now
Registered
65th of 67
by date
Lead sponsor
36 of 67
AstraZeneca

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 47th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2022, is one of 15 in phase 3, and was the 65th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.

Read the detailed description

Esomeprazole (NEXIUM™) is indicated for the maintenance of healing of endoscopy-verified erosive esophagitis (EE) in children 1 to 11 years of age in a number of countries worldwide, but not in the United States (US). The current study has been designed, in discussions with the Food and Drug Administration (FDA), to further evaluate the safety and efficacy of NEXIUM given as maintenance of healing of EE in children 1 to 11 years of age

Safety assessments will include the monitoring of adverse events throughout the study, clinical laboratory testing (including hematology, clinical chemistry, urinalysis), vital signs (including blood pressure and pulse), and physical examination including weight.

03

Conditions studied

  • Erosive Esophagitis

Keywords

  • Erosive Esophagitis
  • Gastroesophageal Reflux Disease
  • Healing
  • Maintenance
  • Esophagogastroduodenoscopy
  • Endoscopy
  • EGD
  • GERD
  • GERD in children
04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be 1 to 11 years of age
  2. Patients must have a clinical history of GERD for at least 3 months before the start of study
  3. For the healing phase: Patients must have confirmed presence of EE at endoscopy performed within one week of the start of the healing phase.
  4. For the maintenance phase: Patients must have completed the healing phase and have endoscopy-verified healed EE at the 8-week endoscopy visit.
  5. Patients must weigh ≥ 10 kg.
  6. Patients may be male or female.
  7. All postmenarcheal female patients must have a negative pregnancy test (urine) before starting treatment.
  8. Sexually active patients must be abstinent or maintain effective from day up to the last day of study intervention.
  9. Patient's guardian must be capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Presence of other diseases, such as severe heart, lung, liver, renal, blood, or neurological disease or similar
  2. Significant clinical illness within 4 weeks prior to the start of treatment
  3. Any conditions that are predicted to require a surgery during the study period (from the day of to the day of the last scheduled visit)
  4. Previous total gastrectomy
  5. Anticipated need for concomitant therapy with PPIs (except for the IMPs), H2-receptor antagonists and other drugs outlined in EC#5 after enrollment in this study
  6. Participation in another clinical study with an IMP administered in the last 4 weeks before enrollment.
  7. Patients with a known to NEXIUM, or any other PPI, or any of the of the product
  8. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  9. Judgment by the Investigator that the patient should not participate in the study if the patient or guardian is unlikely to comply with study procedures, restrictions, and requirements
  10. Previous screening, or enrollment and randomization in the present study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    Nexium - high dose

    Arm 1 (High dose = Healing dose)

    Drug: Nexium 20mg

  • Active comparator
    Nexium - Low dose

    Arm 2 (Low dose = ½ healing dose)

    Drug: Nexium 10mg

Interventions

  • Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.

  • Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Presence / absence of Erosive Esophagitis

    Presence/absence of Erosive Esophagitis for all patients by assessment of Esophagogastroduodenoscopy at the end of the 16-week maintenance phase

    Time frame: Week 24 (end of 16-week maintenance phase)

Secondary outcomes

  1. Presence/absence of Erosive Esophagitis

    Presence/absence of Erosive Esophagitis for all patients by assessment of Esophagogastroduodenoscopy at the end of the 8-week healing phase

    Time frame: Week 8 (end of healing phase)

  2. Percentage of days without rescue medication

    The percentage of days without rescue medication during the 8-week healing phase and during the 16-week maintenance phase

    Time frame: Week 8 (end of healing phase) and Week 16 (end of maintenance phase)

07

Study locations

41 sites
  • Research Site
    Mobile, Alabama 36604, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Miami, Florida 33122, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Carmel, Indiana 46290, United States
  • Research Site
    Shreveport, Louisiana 71103, United States
  • Research Site
    The Bronx, New York 10468, United States
  • Research Site
    Akron, Ohio 44308, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Córdoba, X5016KEH, Argentina
  • Research Site
    Paraná, 3100, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Namur, 5101, Belgium
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Thessaloniki, 54642, Greece
  • Research Site
    Thessaloniki, 56249, Greece
  • Research Site
    Messina, 98124, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Naples, 80138, Italy
  • Research Site
    Roma, 00137, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Vilnius, LT-08406, Lithuania
  • Research Site
    Coimbra, 3000-602, Portugal
  • Research Site
    Lisbon, 1169-045, Portugal
  • Research Site
    Lisbon, 1500-650, Portugal
  • Research Site
    Lisbon, 1998-018, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Porto, 4200-319, Portugal
  • Research Site
    Viana do Castelo, 4901-858, Portugal
  • Research Site
    Badalona, 08916, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hanoi, 10000, Vietnam
  • Research Site
    Hà Nội, 100000, Vietnam
  • Research Site
    Hochiminh, 700000, Vietnam
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2026, 49 months.

Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2022
First posted
Mar 4, 2022
StartActual
Jul 1, 2022
Primary completionActual
Aug 10, 2026
CompletionActual
Aug 10, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Primary completion
Aug 14, 2026→Aug 10, 2026 (actual)
Oct 13, 2026
Study completion
Aug 19, 2026→Aug 10, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Primary completion Aug 14, 2026→Aug 10, 2026 (now actual)
    Study completion Aug 19, 2026→Aug 10, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05267613
Lead sponsor
AstraZeneca
Collaborators
IQVIA RDS Inc., Calyx, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, Inc, CISCRP, Quipment Inc., Little Journey Ltd.
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Jul 1, 2022
Primary completion
Aug 10, 2026
Completion
Aug 10, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion